NCT06334757

Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure

A Multi-center, Open-label, Single-arm Study to Evaluate the Efficacy and Safety of Serplulimab Plus Bevacizumab and Chemotherapy for EGFRm+ Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 46 (estimated)
• Sponsor: Henan Cancer Hospital · Other Government
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of Serplulimab Plus Bevacizumab and chemotherapy in TKI-resistant EGFR-mutated non-squamous NSCLC Chinese patients.

Conditions

• Non-Squamous Non-Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Serplulimab	300 mg，IV，Q3W
DRUG	Bevacizumab Biosimilar HLX04	7.5 mg/kg，Q3W
DRUG	Pemetrexed	500 mg/m2，IV，Q3W
DRUG	Carboplatin	AUC=5，IV，Q3W

Timeline

• Start date: 2023-05-08
• Primary completion: 2024-08-31
• Completion: 2025-06-30
• First posted: 2024-03-28
• Last updated: 2024-03-28

Locations

1 site across 1 country: China